You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior reAlready a subscriber Login You have read all your free articles,…
Orion Corporation and the Finnish Red Cross Blood Service have concluded an agreement on research collaboration with the aim of developing chimeric antigen receptor (CAR) T-cell therapy. The Blood Service has experience in cell research, in the supply of cord blood and stem cell grafts classifiedAlready a subscriber Login You…
In the middle of July the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung cancer (SCLC). About SCLC SCLC constitutes about 15% of all lung cancer diagnoses. It is the most aggressive type of lung cancer with…
Danish, and Nordic, giant Novo Nordisk has presented its results for the fourth quarter of 2018 – a little lower than expected and the company intends to initiate a new 12-month share repurchase programme of up to DKK 15 billion. The company's operating profit increased by 6% measured in local…
